Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/b-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancer cell lines (n ¼ 9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on b-catenin/ T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation-associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).
. Only a small proportion of colorectal cancer cases are attributable to familial cancer syndromes, whereas the majority are considered sporadic. A genetic model involving the alteration of several oncogenes and tumor suppressor genes, which describes the transition from healthy colonic epithelia through increasingly dysplastic adenoma to malignant cancer, was proposed 15 years ago (Fearon and Vogelstein, 1990) . Later studies have basically confirmed this model, and also added new genes and proposed the existence of others, still uncharacterized, as complementary driving forces for this neoplasia . Constitutive activation of Wnt/b-catenin signaling occurs in nearly all colorectal tumors due to mutations in either the APC (Adenomatous Polyposis Coli) gene or less frequently b-catenin/CTNNB1 or AXIN2 . Activation of this pathway is an early, if not initiating, event in tumorigenesis, and APC has been proposed to function as a 'gatekeeper' gene regulating the entry of colonic epithelial cells into the adenoma-carcinoma progression (Kinzler and Vogelstein, 1996) .
Wnt proteins are a family of secreted signaling factors with multiple functions in development and homeostasis (Miller, 2002) . Wnt binding to frizzled receptors and LRP5/6 co-receptors leads to the cytosolic stabilization and accumulation of b-catenin, which translocates to the nucleus and forms a complex with T-cell factor (TCF) transcription factors, thereby regulating target gene expression. Negative regulators of this pathway include glycogen synthase kinase-3b (GSK-3b), the tumor suppressor gene product APC and Axin. Several classes of secreted factors that modulate Wnt action outside the cell have been described, including Cerberus, Wnt inhibitor factor-1 (WIF-1) and members of the secreted frizzled-related protein (sFRP) and Dickkopf (Dkk) families (Kawano and Kypta, 2003) . Dickkopf-1 binds to LRP5/6 and Kremen proteins, thus inducing lowdensity lipoprotein receptor-related protein (LRP) endocytosis and preventing signaling to b-catenin (Bafico et al., 2001; Mao et al., 2001 Mao et al., , 2002 Semenov et al., 2001) . In the mouse intestine, Wnt signals are involved in the proliferation of epithelial progenitor cells at the bottom of the crypts, whereas forced expression of Dkk-1 inhibits cell proliferation and the generation of secretory lineages (Pinto et al., 2003; Kuhnert et al., 2004) . We and others have recently shown that the DKK-1 gene is a target of the b-catenin/TCF signaling pathway (Niida et al., 2004; Chamorro et al., 2005; Gonza´lez-Sancho et al., 2005) . In addition, we reported that DKK-1 expression is downregulated in human colon cancer (Gonza´lez-Sancho et al., 2005) . To address whether epigenetic mechanisms were responsible for DKK-1 downregulation, we have now studied the pattern of CpG island methylation of the DKK-1 promoter and its expression at the RNA and protein levels in human colon cancer cells, and its relation with two other Wnt inhibitors undergoing methylationassociated silencing, SFRP1 and WIF-1.
DKK-1 is a candidate gene for hypermethylationassociated transcriptional inactivation in human cancer since a 5 0 -CpG island is located around its transcription start site and it has been previously reported to be downregulated in human colon cancer (Gonza´lez-Sancho et al., 2005) . To analyse the methylation status of the DKK-1 promoter-associated CpG island, we first screened normal colorectal mucosa (n ¼ 5), normal lymphocytes (n ¼ 5) and human colorectal cancer cell lines (n ¼ 9) using bisulfite genomic sequencing with primers encompassing the transcription start site. None of the normal tissues showed methylation at the DKK-1 CpG island. In contrast, four of the colon cell lines tested, DLD-1, SW48, COLO 205 and CT26, showed hypermethylation of the DKK-1 promoter, while five of them, SW480, LS 174T, HT-29, LoVo and SW620, were unmethylated (Figure 1a and b) . The CpG island methylation status was also confirmed by methylationspecific polymerase chain reaction (PCR) (Figure 1c) . Strikingly, the four cell lines showing DKK-1 gene promoter methylation were established from advanced tumors, Duke's C and D stages, whereas three out of the five lines with unmethylated DKK-1 gene correspond to more initial stages of colorectal tumorigenesis, Duke's B (Figure 1 and Table 1 ). To assess whether methylation of DKK-1 promoter was associated with transcriptional silencing, we analysed DKK-1 RNA expression in the presence or absence of the demethylating agent 5-aza-2-deoxycytidine. Expression of DKK-1 in colon cancer cells is consistent with epigenetic regulation, being either undetectable or very low in lines where its promoter is hypermethylated as compared to those where it is unmethylated (Figure 1d ). Treatment of non-expressing cells such as COLO 205, DLD-1 and SW48 with 5-aza-2-deoxycytidine restored the expression of DKK-1 RNA (Figure 1d ). Western blot and immunofluorescence experiments, using the goat anti-DKK-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), also confirmed the tight association between DKK-1 CpG island promoter hypermethylation and loss of DKK-1 expression: the DKK-1-unmethylated cell line SW480 demonstrated a strong DKK-1 signal, whereas no expression of DKK-1 was observed in the hypermethylated DLD-1 cell line ( Figure 1d ). Most important, in DLD-1 cells DKK-1 expression was restored by treatment with the demethylating agent 5-aza-2-deoxycytidine ( Figure 1d ).
Modifications in the histone tails, such as lysine acetylation and methylation among others, are also key determinants of the active or silenced state of any given gene (Ballestar and Esteller, 2002) . To assess whether the histone modification status of DKK-1 in nonexpressing cells was different from that of expressing cells, we performed chromatin immunoprecipitation analysis using an antibody raised against acetyl histone H3 in cell lysates from DLD-1 and SW480 cells (Figure 1e ). In the latter, the unmethylated CpG island for DKK-1 was associated with enhanced amounts of acetylated histone H3 and active transcription, whereas in DLD-1 cells, histone H3 hypoacetylation was associated with CpG island hypermethylation and transcriptional silencing (Figure 1e ).
Mutations in intracellular components of the Wnt/ b-catenin pathway are thought to cause constitutive downstream signaling independent of upstream signals. Recently, however, involvement of upstream signal regulation in colorectal cancer has been reported, involving, for example, the extracellular Wnt inhibitors, SFRP-1 and WIF-1 (Suzuki et al., 2002; Bafico et al., 2004; Suzuki et al., 2004) . Furthermore, these last two genes have also been recently reported to be silenced by promoter hypermethylation in cancer cell lines and tumors (Suzuki et al., 2002; Mazieres et al., 2004) . Thus, we also analysed the SFRP-1 and WIF-1 CpG island methylation status in our set of colon cell lines. Our results showed that in contrast to DKK-1, SFRP-1 promoter was methylated in all cell lines (nine of nine) and WIF-1 in eight out of nine ( Figure 1c) with independence of the clinical stage of the colorectal tumor from which they were derived.
From a functional standpoint, overexpression of a Wnt1 transgene in a b-catenin mutant cell line results in increased b-catenin/TCF-dependent transcription . In addition, Wnt1 downregulation/ inhibition by short interfering RNA or by a monoclonal anti-Wnt1 antibody induced apoptosis in colon cancer cell lines containing downstream mutations . Moreover, restoration of sFRPs expression in colon cancer cell lines carrying b-catenin/CTNNB1 or APC mutations resulted in suppression of b-catenin/ TCF-dependent transcription (Bafico et al., 2004; Suzuki et al., 2004) . To analyse whether DKK-1 restoration could interfere with b-catenin/TCF-dependent transcription, we studied the effect of exogenous DKK-1 expression in DKK-1 hypermethylation-silenced DLD-1 cells, which carry a truncated APC gene. In contrast to sFRPs, DKK-1 expression could not inhibit basal b-catenin/TCF-dependent transcription in these cells at any dose tested (not shown). Exogenous expression of either Wnt1 or a mutant non-degradable b-catenin, lacking a GSK-3b phosphorylation site (S37Y), had minimal effect on basal b-catenin/TCFdependent transcription (not shown). Similar results were obtained in DKK-1-unmethylated and DKK-1-expressing SW480 cells, which also carry a truncated APC gene. In control human embryonic kidney 293T cells, exogenous DKK-1 expression inhibited Wnt-induced but, not mutant b-catenin-induced DKK-1 methylation in human colorectal cancer O Aguilera et al Figure 1 Epigenetic silencing of DICKKOPF-1 (DKK-1) in colon cancer cells. We determined DKK-1 CpG island methylation status by polymerase chain reaction (PCR) analysis of bisulfite-modified genomic DNA, which induces chemical conversion of unmethylated, but not methylated, cytosine to uracil, using two procedures: bisulfite genomic sequencing and methylation-specific PCR (Ballestar et al., 2003; Fraga et al., 2005) . In (a) and (b), methylation status was analysed by bisulfite genomic sequencing of both strands of the DKK-1 CpG island. The primers used were 5 0 -ggg gtg aag agt gtt aaa ggt t-3 0 (sense) and 5 0 -aaa cca tca tct caa aaa aac tca a-3 In (c), the second analysis used methylation-specific PCR with primers specific for either the methylated or modified unmethylated DNA. Primer sequences of DKK-1 for the unmethylated reaction were 5 0 -ttt taa ggg gtt gga atg ttt t-3 0 (sense) and 5 0 -cca caa aac cat acc aat tca ac-3 0 (antisense), and for the methylated reaction, 5 0 -tta agg ggt cgg aat gtt tc-3 0 (sense) and 5 0 -cac gaa acc gta ccg att c-3 0 (antisense). Methylation-specific PCR primers for the CpG islands of WIF-1 and SFRP-1 genes are described elsewhere (Suzuki et al., 2002; Mazieres et al., 2004) . U and M refer to unmethylated and methylated alleles, respectively. In vitro-methylated DNA (IVD) was used as positive control, and NL as unmethylated control. All three genes were unmethylated in normal colon mucosa (NC). (d) Reverse transcription-PCR analysis for basal DKK-1 gene expression and reactivation after treatment with the demethylating agent 5-aza-2-deoxycytidine. The DKK-1 RT-PCR primers used were 5 0 -gat cat agc acc ttg gat ggg-3 0 (forward) and 5 0 -ggc aca gtc tga tga ccg g-3 0 (reverse). The unmethylated DKK-1 cell lines SW480 expresses the transcript. Restoration of DKK-1 gene expression is observed in the hypermethylated cell lines COLO 205, DLD-1 and SW48 after treatment with the demethylating agent. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression is shown as an internal control. Western blot and immunofluorescence experiments for DKK-1. The DKK-1-unmethylated cell line SW480 demonstrates a DKK-1 signal, whereas no expression of DKK-1 is observed in the hypermethylated DLD-1 cell line. DLD-1 cells DKK-1 is restored by treatment with the demethylating agent 5-aza-2-deoxycytidine. (e) Chromatin immunoprecipitation (ChIP) analysis of the histone modification status of the DKK-1 promoter. ChIP was carried out as described previously (Ballestar et al, 2003) . The DKK-1 ChIP primers used were 5 0 -ttt gtt gtc tcc ctc cca ag-3 0 (forward) and 5 0 -atg acc gtc act ttg caa gc-3 0 (reverse). The input and bound fractions are shown. A commercial anti-acetyl histone H3 antibody (Upstate Biotechnologies, Charlottesville, VA, USA) was used. No antibody (nAB) samples are also shown as a negative control. In the cell line SW480, an unmethylated promoter of DKK-1 is enriched in acetylated histone H3, a marker of active transcription, whereas in the DKK-1-methylated DLD-1 cell line, this marker is depleted. GAPDH was used as an internal control.
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O Aguilera et al b-catenin/TCF4-dependent transcriptional activity (not shown). These results suggest that unlike sFRPs, DKK-1 cannot inhibit b-catenin/TCF-dependent transcription in colon cancer cells with downstream mutations. As sFRPs and WIF-1 directly bind Wnt proteins while DKK-1 binds LRP co-receptors, a plausible explanation is that the effect of sFRPs on b-catenin/TCF-induced transcription is achieved through an LRP-independent mechanism, which cannot be mimicked by DKK-1. We next assayed the ability of DKK-1 to suppress tumor growth. To this end, we expressed an exogenous DKK-1 gene in DLD-1 cells, whose endogenous gene is silenced by promoter methylation. We first performed colony-focus assays using cells transfected with a DKK-1 gene construct (pCDNA3.1/V5-HisA/DKK-1) or an empty vector (pCDNA3.1/V5-HisA). DICKKOPF-1 re-expression markedly decreased (45%) colony formation (Figure 2a and b) .
Next, to examine the effect of DKK-1 on tumor growth in vivo, we injected subcutaneously each flank of the same mice with pooled cells stably transfected with an empty vector or the DKK-1 gene. Additionally, another group of animals were injected with cells of a clone (no. 7) of DKK-1-transfected cells expressing highest level of DKK-1. Cells transfected with the empty vector formed tumors rapidly, whereas those stably expressing DKK-1 had much lower tumorigenicity and clone no. 7 cells formed no tumors (Figure 2c) . Together, these results demonstrate that DKK-1 restoration in deficient colon cancer cells reduces colony formation and tumor growth in xenografts and implies a tumor suppressor function for the DKK-1 gene.
Finally, we sought to demonstrate if the pattern of DKK-1 promoter hypermethylation observed in the cell lines, which was restricted to the most advanced tumors, could be extrapolated to human primary tumors. For this purpose, we analysed the DKK-1 CpG island promoter methylation status in a series of 54 unselected human colon tumors including all Duke's stages ( Figure 3 and Table 1 ). In four randomly selected cases, the methylation status was double-checked by bisulfite genomic sequencing of multiple clones (data not shown). Overall, DKK-1 was found hypermethylated in 17% (nine of 54) of all the primary colon neoplasms studied. However, most important, we found DKK-1 CpG island promoter hypermethylation was associated with the most clinically advanced tumors: 24.3% (nine out of 37) of tumors in advanced Duke's C and D stages present hypermethylation of the DKK-1 promoter ( Figure 3 and Table 1 ), while, in contrast, DKK-1 promoter was unmethylated in all Duke's B tumors (17 out of 17) (Fisher's exact test, P ¼ 0.02) (Figure 3 and Abbreviations: DKK-1, DICKKOPF-1; M, methylated; SFRP-1, secreted frizzled-related proteins U, unmethylated; WIF-1, Wnt inhibitory factor-1.
DKK-1 methylation in human colorectal cancer O Aguilera et al Table 1 ). As it occurred with the colon cell lines, this observation was in sharp contrast with the SFRP1 and WIF-1 CpG island hypermethylation patterns in the same primary colon tumors: SFRP-1 promoter was methylated in almost all cases, 89% (48 out of 54), and WIF-1 was also frequently found hypermethylated, 78% (42 of 54), without any correlation with tumor stage (Figure 3 and Table 1 ).
In conclusion, we show that the extracellular Wnt inhibitor DKK-1 undergoes transcriptional silencing by CpG island promoter hypermethylation in colon cancer cells. The DKK-1 epigenetic silencing in colorectal malignancies occurs with independence of the methylation-associated inactivation of other extracellular Wnt inhibitors, such as SFRP-1 and WIF-1, and DKK-1 re-expression cannot inhibit b-catenin/TCF-dependent transcription in colon cancer cells with downstream mutations. In this regard, antitumoral effects of DKK-1 not linked to the inhibition of the Wnt/b-catenin pathway have been proposed in two scenarios Mikheev et al., 2004) . First, DKK-1 expression is induced in non-tumorigenic revertants of HeLa cells, sensitizing these cells to apoptosis by a mechanism that does not involve changes in either b-catenin subcellular localization or b-catenin/TCFdependent transcription (Mikheev et al., 2004) . Second, in b-catenin-deficient human mesothelioma cells, DKK-1 suppresses cell growth and induces apoptotic cell death by activating the JNK pathway . Here, we present a new scenario in which DKK-1 suppresses tumor growth in transfected cells and xenografts independently of its ability to interfere with b-catenin/ TCF transcriptional activity. In this context, our finding of DKK-1 silencing by promoter hypermethylation in colon cancer cells suggests that DKK-1 may have functions important for tumor suppression other than inhibiting canonical Wnt signaling. The characterization of these unknown DKK-1 functions is an open challenging task. What it is even more important, the discovery that, in contrast to SFRP-1 and WIF-1 hypermethylation, DKK-1 CpG island promoter hypermethylation is restricted to advanced stages of colorectal tumorigenesis situates the epigenetic silencing of this gene as one of the very rare examples (Zou et al., 2002; Maeda et al., 2003; Fraga et al., 2004) in which gene hypermethylation is not an early hit, but instead of this it is associated with tumor progression.
Figure 3 DICKKOPF-1 (DKK-1) CpG island promoter is hypermethylated in advanced Duke's stages human colorectal tumors. Methylation-specific polymerase chain reaction (PCR) analysis of the promoter CpG islands of DKK-1, SFRP-1 and WIF-1 genes in primary colorectal tumors. In vitro-methylated DNA (IVD) was used as positive control for methylated genes and normal lymphocytes (NL) and normal colon mucosa (NC) as control for unmethylation.
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